Skip to main content
Clinical Trials/NCT02270450
NCT02270450
Completed
Not Applicable

S1316, Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction

SWOG Cancer Research Network38 sites in 5 countries221 target enrollmentMarch 9, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Constipation, Impaction, and Bowel Obstruction
Sponsor
SWOG Cancer Research Network
Enrollment
221
Locations
38
Primary Endpoint
Number of Days Alive and Outside of the Hospital
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This partially randomized clinical trial studies surgery or non-surgical management in treating patients with intra-abdominal cancer and bowel obstruction. Bowel obstruction is a common problem for advanced cancer patients and can negatively affect quality of life. It is not yet known whether surgery or non-surgical management is the best treatment option for bowel obstruction and can lead to better quality of life.

Detailed Description

This partially randomized clinical trial studies surgery or non-surgical management in treating patients with intra-abdominal cancer and bowel obstruction. Bowel obstruction is a common problem for advanced cancer patients and can negatively affect quality of life. It is not yet known whether surgery or non-surgical management is the best treatment option for bowel obstruction and can lead to better quality of life.

Registry
clinicaltrials.gov
Start Date
March 9, 2015
End Date
October 31, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of Days Alive and Outside of the Hospital

Time Frame: From date of registration up to 91 days

Number of days alive and outside of the hospital

Secondary Outcomes

  • Ability to Eat(Assessed at 5 weeks post registration)
  • Overall Survival(From date of registration to maximum of 53 weeks)
  • MDASI-GI Symptom Assessment(Assessed at 4 weeks post registration)
  • NG Tube Use(During initial hospitalization, from date of registration to a maximum of 53 weeks post registration)
  • Days of NG Tube Use(During entire initial hospitalization (admission to discharge) to a maximum of 53 weeks post registration)
  • Number of Days in Hospital(During initial hospitalization, from date of registration to a maximum of 53 weeks post registration)

Study Sites (38)

Loading locations...

Similar Trials